Tumor-associated macrophages (TAMs) and other myeloid cells that infiltrate neoplastic lesions promote tumor progression and are associated with poor patient prognosis. We have recently demonstrated that trabectedin, a licensed and commercially available anticancer agent, is selectively cytotoxic for TAMs and their circulating precursors (monocytes). The macrophage-depleting effect of trabectedin is a key component of its antitumor activity.
Trabectedin: A drug from the sea that strikes tumor-associated macrophages
Germano, Giovanni;D'Incalci, Maurizio;
2013-01-01
Abstract
Tumor-associated macrophages (TAMs) and other myeloid cells that infiltrate neoplastic lesions promote tumor progression and are associated with poor patient prognosis. We have recently demonstrated that trabectedin, a licensed and commercially available anticancer agent, is selectively cytotoxic for TAMs and their circulating precursors (monocytes). The macrophage-depleting effect of trabectedin is a key component of its antitumor activity.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Allavena Oncoimmulogy.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
505.28 kB
Formato
Adobe PDF
|
505.28 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
